Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Confronting Hereditary Breast and Ovarian Cancer
This FORCE-endorsed book was written by founder and Executive Director Sue Friedman; geneticist Rebecca Sutphen, MD; and health writer, Kathy Steligo. This book is a comprehensive resource on all topics related to hereditary cancer, genetic testing, and risk-management.
FORCE letter to the FDA on Ovarian Cancer Screening
FORCE response to FDA statement on ovarian cancer screening
Improving Ovarian Cancer Screening
2014 Joining FORCEs Against Hereditary Cancer Newsletter article on the use of HE4 in ovarian cancer screening.
What's New in Hereditary Cancer Research?
Presentation by Dr. Mark Greene on current ovarian cancer screening research.
GOG-0199: The National Ovarian Cancer Prevention and Early Detection Study
Article from Spring 2012 Joining FORCEs Newsletter with updates on the research from GOG-199, a large, multicenter study on ovarian cancer detection and prevention.
Does ovarian cancer start in the fallopian tubes? How does this affect screening and prevention?
2011 Webinar. Dr. Kauff discusses the latest research and expert opinions on whether most hereditary ovarian cancer begins in the fallopian tubes and approaches to ovarian cancer screening based on these findings
Testing for Early Stage Ovarian Cancer
Article from 2008 Summer edition of Joining FORCEs Newsletter on the progress on early detection tests for ovarian cancer.
Ovarian Cancer Prevalence and Early Detection
Summer 2006 Joining FORCEs Newsletter article about efforts to develop early detection for ovarian cancer for high-risk women.
Decision Tool for Women with BRCA Mutations
Developed by researchers at Stanford University, this tool is designed to help women with BRCA mutations understand the risks and survival benefits for each risk-management option in order to make the decision that is right for them.
National Comprehensive Cancer Network
The National Comprehensive Cancer Network is a consortium of experts in the field of oncology. The NCCN publishes a consensus guide for risk management options in high risk women with input from the top geneticists and experts in high-risk management.
The FDA recommends against using screening tests for ovarian cancer screening: FDA Safety Communication
2016 FDA safety communication on ovarian cancer screening